Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ningxia Medical Univ. MLKL compound 9
- Development stage
- Unknown
- Lead developer
- Ningxia Medical University
01
Overview
Ningxia Medical Univ. MLKL compound 9: sourced facts only. name: "As a result, compounds 9 and 14 showed the best activity (EC50 = 148.4 and 595.9 nM) against necroptosis among the analogues by covalently binding to MLKL." [PMID:38442525]; target: "As a result, compounds 9 and 14 showed the best activity (EC50 = 148.4 and 595.9 nM) against necroptosis among the analogues by covalently binding to MLKL." [PMID:38442525]; developer: "School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China." [PMID:38442525]
02
Targets
MLKL (Mixed lineage kinase domain-like protein)
Beyond the preview
Go deeper on Ningxia Medical Univ. MLKL compound 9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningxia Medical Univ. MLKL compound 9.